A biomarker that
can help predict the success of chemotherapy in ovarian cancer patients has
been discovered by researchers.
The
discovery, by cancer researcher Madhuri Koti of Queen’s University, could lead
to better treatment options in the fight against ovarian cancer.
Biomarkers
are an indicator of a biological state or condition.
"Recent successes in harnessing the immune system to combat
cancer are evidence for the significant roles of a cancer patient's immune
responses in fighting cancer," Koti explains. "Many of these
successes are based on boosting anti-cancer immunity via different therapies.
Such therapies would prove to be most effective when coupled with markers
predicting a patient's eventual response to a specific therapy".
Koti conducted the study in retrospective cohorts of more
than 200 ovarian cancer patients. The study utilized a combination of
cutting-edge and more established detection technologies for identifying such
markers.
A
major impact of this discovery is that these novel markers, when used at the
time of treatment initiation in the specific type of ovarian cancer patient,
will help oncologists make decisions on additional treatment needed in these
patients, thus increasing their potential for survival.
Ovarian
cancer is responsible for approximately 152,000 deaths worldwide each year. It
has the highest mortality rate of all gynaecological cancers.
For our BCC
Research reports on cancer or biomarkers, visit the following links:
Therapeutics for 'Silent' Cancers (PHM169A)
Posts
No comments:
Post a Comment